Axonics Modulation Technologies Inc at Bank of America Merrill Lynch Health Care Conference Transcript
Good morning. My name is Raymond Cohen. I'm the Chief Executive Officer and Co-Founder of Axonics Modulation Technologies. We are pleased to be here at the BofA Conference today and appreciate for people to attend the session and for listening in on the webcast.
So just briefly in terms of a bit of an overview on Axonics. We are focused on the market of Sacral Neuromodulation. This is primarily a woman's health issue. There are approximately 47 million women who are suffering from either urinary or fecal incontinence or some variation of that theme. Sacral Neuromodulation has been around for a long time. It's fully reimbursed in the United States by Medicare and all private insurance carriers. Medtronic is currently the only player in the marketplace. And Axonics has come onto the scene here with the first and only rechargeable system that is designed to last at least 15 years in the body. This is important because the incumbent has a nonrechargeable device that needs to get explanted on average every 3 to 5 years. So we
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |